Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Akebia Therapeutics (AKBA) Enterprise Value: 2016-2024

Historic Enterprise Value for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $362.7 million.

  • Akebia Therapeutics' Enterprise Value rose 128.85% to $557.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $254.8 million, marking a year-over-year increase of 113.89%. This contributed to the annual value of $362.7 million for FY2024, which is 90.20% up from last year.
  • Per Akebia Therapeutics' latest filing, its Enterprise Value stood at $362.7 million for FY2024, which was up 90.20% from $190.7 million recorded in FY2023.
  • Akebia Therapeutics' Enterprise Value's 5-year high stood at $362.7 million during FY2024, with a 5-year trough of $15.7 million in FY2022.
  • Its 3-year average for Enterprise Value is $189.7 million, with a median of $190.7 million in 2023.
  • As far as peak fluctuations go, Akebia Therapeutics' Enterprise Value crashed by 93.62% in 2022, and later spiked by 1,116.05% in 2023.
  • Over the past 5 years, Akebia Therapeutics' Enterprise Value (Yearly) stood at $176.0 million in 2020, then surged by 39.54% to $245.6 million in 2021, then plummeted by 93.62% to $15.7 million in 2022, then skyrocketed by 1,116.05% to $190.7 million in 2023, then soared by 90.20% to $362.7 million in 2024.